Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROSY-T: Roll Over Study of Osimertinib in Cancer Patients
NCT05629234Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- May 2023
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 3 trial of osimertinib in cancer, sponsored by AstraZeneca. Started May 2023; status: active, not recruiting.
02
Drugs
03
Conditions
cancer
Beyond the preview
Go deeper on NCT05629234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05629234.